4-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-butan-2-one | 92601-47-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-butan-2-one
• 英文别名: 2,5,8,11-Tetraoxapentadecan-14-one；4-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]butan-2-one
• CAS: 92601-47-3
• 化学式: C₁₁H₂₂O₅
• 分子量: 234.293
• InChiKey: XBIYUFMSBJBYKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  16
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  三甘醇单甲醚 、 丁烯酮 在 sodium methylate 作用下， 生成 4-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-butan-2-one
  参考文献：
  名称：

  Anzinger,H. et al., Angewandte Chemie, 1979, vol. 91, p. 747 - 748

  摘要：

  DOI：

文献信息

• US20140341804A1
  申请人：——

  公开号：US20140341804A1

  公开（公告）日：2014-11-20
• PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS
  申请人：SEATTLE GENETICS, INC.

  公开号：US20160310612A1

  公开（公告）日：2016-10-27

  The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.
• PEPTIDOMIMETIC MACROCYCLES
  申请人：Aileron Therapeutics, Inc.

  公开号：US20170037105A1

  公开（公告）日：2017-02-09

  The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.
• HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170049912A1

  公开（公告）日：2017-02-23

  The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (∝, ε-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
• PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
  申请人：AILERON Therapeutics, Inc.

  公开号：US20170107252A1

  公开（公告）日：2017-04-20

  The disclosed peptidomimetic macrocycles modulate the activity of MCL-1. Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which MCL-1 is over-expressed, such as cancer. In particular, MCL-1-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by MCL-1 over-expression or hyper-activation.